LIPI- PROTECT-2 : Dietary Supplement in Subjects With Moderate Hypercholesterolemia (LPP2) (LPP2)
Effect of the Dietary Supplement LIPI-PROTECT-2 on Plasma LDL Cholesterol Concentration in Subjects With Moderate Hypercholesterolemia: A Pilot Study.
This is a multicenter, uncontrolled pilot study evaluating changes in plasma LDL-cholesterol (LDL-C) concentrations before and after 3 months of intake of the dietary supplement LIPI-PROTECT-2.The main objective of this clinical trial is to evaluate the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation in participants with untreated moderate hypercholesterolemia.A mean reduction in plasma LDL-C levels of approximately 14% (0.20 g/L) is expected after 3 months of supplementation.The primary endpoint is the absolute (g/L) and relative (%) change in plasma LDL-C concentration between baseline and Month 3.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
Elevated low-density lipoprotein cholesterol (LDL-C) is an established risk factor for coronary cardiovascular disease. In individuals at low cardiovascular risk, lifestyle and dietary measures are recommended to reduce LDL-C levels and/or overall cardiovascular risk. Dietary supplements may be considered as part of these measures when their efficacy has been demonstrated.LIPI-PROTECT-2 is a dietary supplement containing plant extracts and vitamins that may contribute to reducing plasma LDL-C levels. Some of its individual active ingredients have previously been investigated in clinical studies and have shown an LDL-C-lowering effect. However, the combination of these active ingredients has not previously been evaluated in a clinical study.This pilot, multicenter, uncontrolled study is designed to provide preliminary estimates of the effect of LIPI-PROTECT-2 in adults with untreated moderate hypercholesterolemia.A total of 20 men and women aged 18 to 65 years with untreated moderate hypercholesterolemia will be included. Participants will have an LDL-C level ≥1.5 g/L and a low cardiovascular risk. They will consume LIPI-PROTECT-2 for 3 months and will be required to maintain stable body weight, dietary habits, and physical activity throughout the study.The primary objective is to assess the effect of LIPI-PROTECT-2 on plasma LDL-C concentration after 3 months of supplementation. The primary outcome will be the absolute and relative change in LDL-C concentration between baseline and Month 3. A mean reduction of approximately 14% (0.20 g/L) in LDL-C is expected after 3 months of supplementation.Secondary objectives are to evaluate the effect of LIPI-PROTECT-2 after 1 and 3 months compared with baseline on body weight, body mass index, waist circumference, systolic and diastolic blood pressure, resting heart rate, fasting glucose, LDL-C, non-HDL cholesterol, total cholesterol, HDL cholesterol, triglycerides, LDL-C/HDL-C and total cholesterol/HDL-C ratios, and the atherogenic index (non-HDL-C/HDL-C).Safety will also be assessed by comparing selected laboratory parameters between baseline and Month 3, including AST, ALT, gamma-glutamyl transferase, creatine kinase, lactate dehydrogenase, bilirubin, creatinine, and urea. Adherence to the dietary supplement will be assessed throughout the study.Participants with high or very high cardiovascular risk, lipid-lowering treatment, diabetes, severe chronic diseases, or concomitant treatments likely to interfere with the assessment of efficacy or safety will be excluded.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: Coralie BERTHIER, PhD
- Puhelinnumero: +33 0320877333
- Sähköposti: coralie.berthier@pasteur-lille.fr
Tutki yhteystietojen varmuuskopiointi
- Nimi: Frédéric BATTEUX, MD
- Puhelinnumero: +33 320877316
- Sähköposti: frederic.batteux@pasteur-lille.fr
Opiskelupaikat
-
-
Nord
-
Lille, Nord, Ranska, 59019
- Rekrytointi
- Prevention research center - Institut Pasteur of Lille
-
Ottaa yhteyttä:
- Coralie BERTHIER, PhD
- Puhelinnumero: +33 0320877333
- Sähköposti: coralie.berthier@pasteur-lille.fr
-
Ottaa yhteyttä:
- Bérengère LEGENDRE
- Puhelinnumero: +33 0320877346
- Sähköposti: berengere.legendre@pasteur-lille.fr
-
Päätutkija:
- Frédéric BATTEUX, MD
-
-
Vaucluse
-
Avignon, Vaucluse, Ranska, 84140
- Rekrytointi
- Biophysium Avignon
-
Ottaa yhteyttä:
- Gaetan BOLEA, PhD
- Puhelinnumero: +33 0660663995
- Sähköposti: g.bolea@biophysium.com
-
Ottaa yhteyttä:
- Romain CAYUELA, MD
- Puhelinnumero: +33 0629355794
- Sähköposti: docteur.cayuelaromain@gmail.com
-
Päätutkija:
- Romain CAYUELA, MD
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
- Men and women aged 18-65 years For women :If pre-menopausal: effective non-estrogenic* contraception initiated at least 2 cycles prior and maintained throughout the studyIf post-menopausal: not receiving estrogenic* Hormone Replacement Therapy (HRT)
- LDL-cholesterol ≥ 1.5 g/L (calculated using the Friedewald formula)
- Aware of their hypercholesterolemia and previously informed about the associated lifestyle and dietary measures
- BMI between 20 and 35 kg/m² (inclusive)
- Stable weight, dietary habits, and physical activity level for at least 3 months prior to the start of the study, with agreement to maintain them throughout the study
- Willing to comply with study requirements
- Signed informed consent
Exclusion Criteria:
- Subjects receiving lipid-lowering or anti-dyslipidemic therapy (statins, ezetimibe, cholestyramine, fibrates, etc.)
- Subjects with triglyceride levels > 4 g/L
- Subjects requiring immediate lipid-lowering therapy
- Subjects with diabetes (whether treated with medication or not, or diagnosed during the initial visit based on fasting blood glucose > 1.26 g/L)
- Subjects receiving beta-blockers and/or diuretics
- Subjects at high or very high cardiovascular risk according to ESC/EAS 2025 guidelines (assessed using the SCORE2 score, Appendix 2)
- Subjects receiving anticoagulant therapy
- Subjects receiving antiretroviral therapy
- Subjects requiring immediate dietary intervention, or exhibiting fluctuating eating habits or an eating disorder (anorexia, bulimia, binge eating disorder)
- Subjects on unstable treatment (initiated less than three months prior) or requiring the initiation of treatment during the study that, in the investigator's opinion, could interfere with the assessment of study endpoints (efficacy parameters: LDL, TG, HDL, blood glucose, blood pressure, weight; safety parameters: markers of hepatic, muscular, or renal function)
- Subjects who have consumed dietary supplements or functional foods capable of affecting cholesterol or triglyceride levels (phytosterols, phytostanols, red yeast rice, policosanols, beta-glucans at doses exceeding 3 g/day, artichoke or garlic extracts, probiotics, etc.) within the last 6 weeks
- Subjects suffering from a severe chronic condition deemed incompatible with participation in the study by the investigator (serious digestive disorders, renal insufficiency, coronary artery disease, immunodeficiency, heart failure, rhythm disorders, active malignancy, hematological disease)
- Subjects with an allergy to any of the components of LIPI-PROTECT-2 Pregnant or breastfeeding women, or women intending to become pregnant within the next 4 months Subjects under legal protection (guardianship/curatorship, deprivation of liberty) or not covered by a social security scheme
- Subjects participating in another clinical study or currently within the exclusion period of another study
- Subjects whose condition is judged by the principal investigator or a qualified co-investigator deems that their health status or concomitant treatments are incompatible with the proper conduct of the clinical study.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Ennaltaehkäisy
- Jako: Ei käytössä
- Inventiomalli: Yksittäinen ryhmätehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Kokeellinen: Food supplement group
Three tablets of LIPI-PROTECT-2 per day (1 at the end or after breakfast and 2 during dinner). Food supplements are consumed during 3 months by healthy volunteers |
All subjects will consume 4 capsules per day during the entire intervention period, i.e. 12 weeks between V0 and V3, distributed as follows: 2 capsules in the morning at the end of or after breakfast (no taking on an empty stomach) and 2 capsules in the evening during dinner. If a dose is missed, 1 capsule can be taken at the next dose |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (absolute value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia
Aikaikkuna: To baseline at 3 months
|
To evaluate the absolute (g/L) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
To evaluate the effect of LIPI-PROTECT-2 on plasma LDL-cholesterol concentration (relative value) after 3 months of consumption in subjects with untreated moderate hypercholesterolemia.
Aikaikkuna: To baseline at 3 months
|
To evaluate the relative (%) change in plasma LDL-cholesterol concentration, measured using the Friedewald method, between baseline (V0) and the end of the 3-month intervention (V3). |
To baseline at 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on LDL cholesterol.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in LDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Non HDL cholesterol.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in Non HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on total cholesterol.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in total cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on HDL cholesterol.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) in HDL cholesterol in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on triglycerides.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on triglycerides in g/L. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on non HDL cholesterol/LDL (atherogenic index).
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non HDL cholesterol/LDL (atherogenic index) (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio LDL/HDL.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on non ratio LDL/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on ratio total cholesterol/HDL.
Aikaikkuna: At baseline, 1 month and 3 months
|
Change from V0 (baseline) to V1 (1 month) and V3 (3 months) on ratio total cholesterol/HDL (ratio). |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on fasting blood glucose levels.
Aikaikkuna: At baseline, 1 month and 3 months
|
Variation in fasting blood glucose (unit: g/l) between VS, V1, and V3 |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on weight.
Aikaikkuna: At baseline, 1 month and 3 months
|
Changes in weight (unit : kilograms) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on Body Mass Index (BMI).
Aikaikkuna: At baseline, 1 month and 3 months
|
Changes in BMI (weight and height will be combined to report BMI) in kg/m^2between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on waist circumference.
Aikaikkuna: At baseline, 1 month and 3 months
|
Changes in waist circumference (unit: cm) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on arterial blood pressure
Aikaikkuna: At baseline, 1 month and 3 months
|
Variation in systolic blood pressure and diastolic blood pressure (unit: mm Hg) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the effect of LIPI-PROTECT-2 on heart rate
Aikaikkuna: At baseline, 1 month and 3 months
|
Variation in Heart rate (unit: Pul/min) between baseline, V1, and V3. |
At baseline, 1 month and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism: ASAT/ALAT, GGT
Aikaikkuna: At baseline and 3 months
|
Changes in safety biomarkers : ASAT/ALAT and GGT(unit: UI/l) between baseline and V3 . |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on hepatic metabolism : Creatinine, bilirubin
Aikaikkuna: At baseline and 3 months
|
Changes in safety biomarkers : Creatinine, bilirubin (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Urea
Aikaikkuna: At baseline and 3 months
|
Changes in safety biomarkers : Urea (unit: mg/dl) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on renal metabolism : Creatinine Phophoskinase (CPK)
Aikaikkuna: At baseline and 3 months
|
Changes in safety biomarkers : CPK (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To evaluate the safety of LIPI-PROTECT-2 on Renal metabolism : Lactate Deshydrogenase (LDH)
Aikaikkuna: At baseline and 3 months
|
Changes in safety biomarkers : LDH (unit : UI/l) between baseline and V3. |
At baseline and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by pillbox weighing
Aikaikkuna: At baseline, 1 month and 3 months
|
Adherence assessed by weighing the pillbox at each visit and comparing the weight with the initial weight recorded at baseline (V0). |
At baseline, 1 month and 3 months
|
|
To assess self-reported adherence to LIPI-PROTECT-2 consumption
Aikaikkuna: At baseline, 1 month, 2 months and 3 months
|
Adherence assessed through participant self-reporting of supplement consumption and missed doses. |
At baseline, 1 month, 2 months and 3 months
|
|
To assess adherence to LIPI-PROTECT-2 consumption by counting returned tablets
Aikaikkuna: At 3 months
|
Adherence assessed by counting the remaining tablets returned by participants at the end of the study. |
At 3 months
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Tutkijat
Tutkijat
- Opintojen puheenjohtaja: Coralie BERTHIER, PhD, Institut Pasteur of Lille
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
- Aineenvaihdunta, synnynnäiset virheet
- Geneettiset sairaudet, synnynnäiset
- Metaboliset sairaudet
- Hyperlipidemiat
- Dyslipidemiat
- Lipidiaineenvaihduntahäiriöt
- Lipidiaineenvaihdunta, synnynnäiset virheet
- Hyperlipoproteinemiat
- Synnynnäiset, perinnölliset ja vastasyntyneiden sairaudet ja poikkeavuudet
- Ravitsemukselliset ja aineenvaihduntataudit
- Hyperkolesterolemia
- Hyperlipoproteinemia tyyppi II
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 2026-A00950-51
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .